Serum S-100β as a possible marker of blood–brain barrier disruption

Kapural, Miranda; Krizanac-Bengez, Lj; Barnett, Gene H.; Perl, John; Masaryk, Thomas; Apollo, D; Rasmussen, Peter A.; Mayberg, Marc R.; Janigro, Damir

doi:10.1016/s0006-8993(02)02586-6

Cited by 262 publications

(181 citation statements)

References 11 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…MicroRNAs (miRNAs) are endogenous small RNAs of approximately [18][19][20][21][22][23] nucleotides that bind to the 3′-untranslated region of messenger RNAs of protein-coding genes to downregulate their expression (2,4). miRNAs play an important role in various physiological and pathological processes (9,20).…”

mentioning

confidence: 99%

Plasma miR-124 as a biomarker for cerebral infarction

et al. 2011

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous small RNAs that play an important role in various physiological processes by downregulating target genes. Recently, plasma miRNAs have been investigated as biomarkers for various diseases. In this study, miRNA array analysis in various tissues showed that miR-124 is almost exclusively expressed in the central nervous system and neuronal cells, suggesting that it might be useful as a potential biomarker for neurological diseases. We examined whether plasma concentrations of brain-specific miRNA can serve as a biomarker for cerebral infarction, where the cerebral infarction was modeled by middle cerebral artery occlusion (MCAO) in the rat. Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after MCAO introduction. Thus, plasma concentration of miR-124 provides a promising candidate biomarker for early detection of cerebral infarction.

show abstract

mentioning

confidence: 99%

Plasma miR-124 as a biomarker for cerebral infarction

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, our results would suggest that even in the absence of overt HE and CHE, the cirrhotic patient is at a state of astrocyte activation and swelling, and has increased BBB permeability. Brain adaptation to ammonia insults during early stages of cirrhosis and portal hypertension might consitute the counteracting condition preventing CHE or overt HE [29][30][31] . Our understanding of the cellular mechanisms leading to astrocyte dysfunction and neurotoxicity is limited, and it is unclear whether BBB disruption is crucial in the etiopathogenesis of HE, or an inevitable consequence of the disease itself.…”

Section: Discussionmentioning

confidence: 99%

Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy

Duarte‐Rojo

Ruiz-Margáin

Macías-Rodríguez

et al. 2016

WJG

View full text Add to dashboard Cite

AIM:To evaluate the association between serum concentrations of S100β in patients with cirrhosis and the presence of low grade hepatic encephalopathy (HE). METHODS:This was a cross-sectional study. The population was categorized into four groups healthy subjects, cirrhosis without HE, cirrhosis with covert hepatic encephalopathy (CHE) and cirrhosis with overt HE. Kruskal-Wallis, Mann Whitney's U with Bonferroni adjustment Spearman correlations and area under the ROC were used as appropriate. RESULTS:A total of 61 subjects were included, 46 cirrhotic patients and 15 healthy volunteers. S100β values were different among all groups, and differences remained significant between groups 1 and 2 (P < 0.001), and also between groups 2 and 3 (P = 0.016), but not between groups 3 and 4. In cirrhotic patients with HE S100β was higher than in Observational Study

show abstract

“…However, as an alternative approach, recent studies have reported several biomarkers specific to BBB disruption in serum of patients (e.g. astrocyte-derived protein S-100β 49 and tight junction protein CLDN5 50 ). Assuming such proteins circulating in the blood mirror BBB integrity, accumulated evidence from animal studies may be useful in clinical trials.…”

Section: Future Perspectivementioning

confidence: 99%

Untitled

2017

J Neurol Neuromed

View full text Add to dashboard Cite

Serum S-100β as a possible marker of blood–brain barrier disruption

Cited by 262 publications

References 11 publications

Plasma miR-124 as a biomarker for cerebral infarction

Plasma miR-124 as a biomarker for cerebral infarction

Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy

Untitled

Contact Info

Product

Resources

About